Cancer Incidence Among Users of Glucagon-Like Peptide-1 Receptor Agonists - PubMed
6 days ago
- #diabetes
- #cancer-risk
- #GLP-1RA
- GLP-1 receptor agonists (GLP-1RAs) are antidiabetic agents that may influence cancer risk.
- A retrospective cohort study analyzed 106,088 type 2 diabetes patients (2013-2021) comparing GLP-1RA users to insulin users.
- GLP-1RA use was associated with a significantly lower risk of liver cancer (HR: 0.47) and pancreatic cancer (HR: 0.23).
- No increased risk was observed for other major cancers (thyroid, lung, breast, colorectal, etc.).
- Further research is needed to define the long-term cancer-related safety profile of GLP-1RAs.